Philina Lee
Director/Board Member at FUSN PHAR
Net worth: 3 M $ as of 2024-04-29
Profile
Philina Lee is an Independent Director at Fusion Pharmaceuticals, Inc. since 2021.
She is also the Chief Commercial Officer at Blueprint Medicines Corp.
since 2014.
Previously, she worked at Algeta ASA as the Head-US Marketing.
Dr. Lee holds a doctorate degree from the Massachusetts Institute of Technology and an undergraduate degree from the University of Alberta.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-03-12 | 34,729 ( 0.06% ) | 3 M $ | 2024-04-29 | |
| 2024-04-02 | 0 ( -.--% ) | - $ | 2024-04-29 |
Philina Lee active positions
| Companies | Position | Start |
|---|---|---|
| FUSN PHAR | Director/Board Member | 2021-02-10 |
| BLUEPRINT MEDICINES CORPORATION | Corporate Officer/Principal | 2020-12-31 |
Former positions of Philina Lee
| Companies | Position | End |
|---|---|---|
| ALGETA ASA | Corporate Officer/Principal | - |
Training of Philina Lee
| University of Alberta | Undergraduate Degree |
| Massachusetts Institute of Technology | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| FUSN PHAR | Health Technology |
| BLUEPRINT MEDICINES CORPORATION | Health Technology |
| Private companies | 1 |
|---|---|
Algeta ASA
 Algeta ASA Pharmaceuticals: MajorHealth Technology Algeta ASA is engaged in the development of products for the treatment of cancer. The company focuses on the development of anti-cancer drugs, and its research and development of compounds focuses on the various applications of a few base compounds. Its products, Alpharadin and Thorium-227, are being developed for treatment of skeletal metastases originating from prostate and breast cancer. The company was founded by Roy H. Larsen and Øyvind Sverre Bruland in 1997 and is headquartered in Oslo, Norway. | Health Technology |
- Stock Market
- Insiders
- Philina Lee
